Related Experiment Video

Updated: May 25, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy

Cristina E Tognon1, Poul H B Sorensen

  • 1British Columbia Cancer Research Centre , Department of Molecular Oncology, Vancouver, British Columbia, Canada.

Expert Opinion on Therapeutic Targets
|January 14, 2012
PubMed
Abstract

Insights

Targeting the Insulin-like Growth Factor 1 Receptor (IGF1R) shows promise in cancer therapy. Early trials indicate modest efficacy, with ongoing research exploring combination therapies and patient selection for improved outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The Insulin-like Growth Factor (IGF) system regulates growth and development.
  • Dysregulated IGF1 receptor (IGF1R) signaling is implicated in numerous cancers.
  • IGF1R inhibition is a focus of current cancer therapy trials.

Purpose of the Study:

  • To review canonical and non-canonical IGF1R signaling pathways in carcinogenesis.
  • To discuss novel insights into IGF1R signaling, including hybrid receptor formation and nuclear translocation.
  • To explore strategies for targeting IGF1R and overcoming resistance.

Main Methods:

  • Review of IGF signaling pathways in cancer.
  • Analysis of recent findings on IGF1R and Insulin Receptor (INSR) interactions.
  • Examination of therapeutic approaches and resistance mechanisms.

Main Results:

  • Pre-clinical studies support IGF1R as a viable cancer target.
  • Early clinical trials demonstrate modest therapeutic benefits in specific cancer types.
  • IGF1R signaling contributes to carcinogenesis through various mechanisms.

Conclusions:

  • Further research is needed on dual IGF1R/INSR targeting.
  • Biomarker development is crucial for identifying responsive patients.
  • Combination therapies involving IGF1R inhibitors show potential.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...